| Date Filed | Type | Description |
| 01/26/2018 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/09/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/09/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/09/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/04/2018 |
8-K
| Quarterly results |
| 12/28/2017 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 12/28/2017 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 12/20/2017 |
8-K/A
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 12/19/2017 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 12/19/2017 |
25
| Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities: |
| 11/17/2017 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits |
| 11/13/2017 |
10-Q
| Quarterly Report for the period ended September 30, 2017 |
| 11/07/2017 |
8-K
| Financial Statements and Exhibits |
| 11/02/2017 |
GN
| Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx – Research Highlights Growth, Revenue, and Consolidated Results |
| 11/01/2017 |
8-K
| Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year,... |
| 10/26/2017 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events |
| 10/23/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/10/2017 |
SC 13D
| Painter Edward H reports a 6.8% stake in Roka Bioscience, Inc |
| 10/05/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/03/2017 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/03/2017 |
8-K
| Resignation/termination of a director |
| 10/02/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 09/29/2017 |
8-K
| Quarterly results |
| 09/28/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 09/27/2017 |
10-Q/A
| Quarterly Report for the period ended June 30, 2017 [amend] |
| 09/27/2017 |
10-Q/A
| Quarterly Report for the period ended March 31, 2017 [amend] |
| 09/27/2017 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
| 09/19/2017 |
8-K
| Quarterly results |
| 09/11/2017 |
SC 13G
| Shansab Tamim reports a 4.7% stake in ROKA BIOSCIENCE, INC. |
| 08/29/2017 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/23/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/18/2017 |
10-Q
| Quarterly Report for the period ended June 30, 2017 |
| 08/17/2017 |
8-K
| Quarterly results |
| 08/14/2017 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
|